Ankylosing spondylitis,Bekhterev's disease,Arthritis,Acutreatment,Cure without medicine,spondyloarthropathies,Signs and symptoms for Ankylosing spondylitis,Acu,Treatment,Cure,Medicine,Disease,chronic inflammatory,autoimmune disease,peripheral joints,nonarticular structures

Ankylosing spondylitis (AS, from Greek ankylos, crooked; spondylos, vertebra; -itis, inflammation), previously known as Bekhterev’s disease and Marie-Strümpell disease, is a chronic inflammatory autoimmune disease of the axial skeleton, with variable involvement of peripheral joints and nonarticular structures. AS is one of the seronegative spondyloarthropathies and has a strong genetic predisposition. It mainly affects joints in the spine and the sacroiliac joint in the pelvis. In severe cases, complete fusion and rigidity of the spine can occur.

“Bamboo spine” develops when the outer fibers of the fibrous ring of the Intervertebral discs ossify, which results in the formation of marginal syndesmophytes between adjoining vertebrae.

Ankylosing spondylitis

Ankylosing spondylitis

Signs and symptoms

The signs and symptoms of ankylosing spondylitis often appear gradually, with peak onset being between 20 and 30 years of age.

The initial symptoms are usually a chronic dull pain in the lower back or gluteal region combined with stiffness of the lower back.

Individuals often experience pain and stiffness that awakens them in the early morning hours.

As the disease progresses, loss of spinal mobility and chest expansion, with limitation of anterior flexion, lateral flexion, and extension of the lumbar spine, are seen.

Systemic features are common, with weight loss, fever, or fatigue often present.

Pain is often severe at rest, but improves with physical activity. However, many experience inflammation and pain to varying degrees regardless of rest and movement.

AS can occur in any part of the spine or the entire spine, often with pain referred to one or the other buttock or the back of the thigh from the sacroiliac joint.

Arthritis in the hips and shoulders may also occur.

When the condition presents before the age of 18, it is relatively likely to cause pain and swelling of large limb joints, particularly the knee.

In prepubescent cases, pain and swelling may also manifest in the ankles and feet, where heel spurs may also develop. Less commonlyectasia of the sacral nerve root sheaths may occur.

About 40% of people with AS will also experience inflammation of the anterior chamber of the eye, causing eye pain, redness, floaters andsensitivity to light. This is thought to be due to the association that both AS and uveitis have with the inheritance of the HLA-B27 antigen.Inflammation of the prostate occurs with increased frequency in men. Cardiovascular involvement may include inflammation of the aorta,aortic valve insufficiency or disturbances of the heart’s electrical conduction system. Lung involvement is characterized by progressive fibrosis of the upper portion of the lung.

As disease onset is generally in early adulthood the effects are present for most of the patient’s life. Progression may continue through what should be economically active years. It is reported that two thirds of male patients have difficulty at work, one third have social problems, and up to two thirds report having difficulty with sexual activity. Reactive depression and frustration are noted, together with impaired self esteem and social skills. Energy related problems are also widely reported. All these features denote significant effects of the disease on lifestyle.

Ankylosing spondylitis

Ankylosing spondylitis

Pathophysiology

Ankylosing spondylitis (AS) is a systemic rheumatic disease, meaning it affects the entire body. Approximately 90% of people with AS express the HLA-B27 genotype, meaning there is a strong genetic association. 1-2% of individuals with the HLA-B27 genotype contract the disease. Tumor necrosis factor-alpha (TNF α) and IL-1 are also implicated in ankylosing spondylitis. Autoantibodies specific for AS have not been identified. Anti-neutrophil cytoplasmic antibodies (ANCAs) are associated with AS, but do not correlate with disease severity.

The association of AS with HLA-B27 suggests the condition involves CD8 T cells, which interact with HLA-B. This interaction is not proven to involve a self antigen, and at least in the related reactive arthritis, which follows infections, the antigens involved are likely to be derived from intracellular microorganisms. There is, however, a possibility that CD4+ T lymphocytes are involved in an aberrant way, since HLA-B27 appears to have a number of unusual properties, including possibly an ability to interact with T cell receptors in association with CD4 (usually CD8+ cytotoxic T cell with HLAB antigen as it is a MHC class 1 antigen).

Diagnosis

There is no direct test to diagnose AS. The Schober’s test is a useful clinical measure of flexion of the lumbar spine performed during the physical examination. Magnetic resonance imaging (MRI), and X-ray studies of the spine, which show characteristic spinal changes and inflammation of the sacroiliac joint, combined with a genetic marker blood test are the major diagnostic tools.

Radiographic features

  • The earliest changes in the sacroiliac joints demonstrable by plain x–ray shows erosions and sclerosis.
  • Progression of the erosions leads to pseudo widening of the joint space and bony ankylosis.
  • X-ray spine can reveal squaring of vertebae with spine ossification with fibrous band run longitudinally called syndesmophyte while produce bamboo spine appearance.
  • A drawback of X-ray diagnosis is the signs and symptoms of AS have usually been established as long as 8–10 years prior to X-ray-evident changes occurring on a plain film X-ray, which means a delay of as long as 10 years before adequate therapies can be introduced. Options for earlier diagnosis are tomography and MRI of the sacroiliac joints, but the reliability of these tests is still unclear.

Blood parameters

During acute inflammatory periods, people with AS may show an increase in the blood concentration of C-reactive protein (CRP) and an increase in the erythrocyte sedimentation rate (ESR), but there are many with AS whose CRP and ESR rates do not increase, so normal CRP and ESR results do not always correspond with the amount of inflammation that is actually present. In other words, some people with AS have normal levels of CRP and ESR, despite experiencing a significant amount of inflammation in their bodies.

Genetic testing

Variations of the HLA-B gene increase the risk of developing ankylosing spondylitis, although it is not a diagnostic test. Those with the HLA-B27 variant are at a higher risk than the general population of developing the disorder. HLA-B27, demonstrated in a blood test, can occasionally help with diagnosis, but in itself is not diagnostic of AS in a person with back pain. Over 95% of people that have been diagnosed with AS are HLA-B27 positive, although this ratio varies from population to population (about 50% of African Americans with AS possess HLA-B27 in contrast to the figure of 80% among those with AS who are of Mediterranean descent

BASDAI

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), developed in Bath (UK), is an index designed to detect the inflammatory burden of active disease. The BASDAI can help to establish a diagnosis of AS in the presence of other factors such as HLA-B27 positivity, persistent buttock pain which resolves with exercise, and X-ray or MRI evident involvement of the sacroiliac joints. (See: “Diagnostic Tools”, below) It can be easily calculated and accurately assesses the need for additional therapy; a person with AS with a score of four out of a possible 10 points while on adequate NSAID therapy is usually considered a good candidate for biologic therapy.

The Bath Ankylosing Spondylitis Functional Index (BASFI) is a functional index which can accurately assess functional impairment due to the disease, as well as improvements following therapy. (See: “Diagnostic Tools”, below) The BASFI is not usually used as a diagnostic tool, but rather as a tool to establish a current baseline and subsequent response to therapy.

Treatment

There is no cure for AS, although treatments and medications can reduce symptoms and pain. It is thought that in some cases a diet low in starches found in flour products and potatoes, and high in proteins and vegetables is of benefit for AS patients.

Medication

The major types of medications used to treat ankylosing spondylitis are pain-relievers and drugs aimed at stopping or slowing the progression of the disease. All of these have potentially serious side effects. Pain-relieving drugs come in two major classes:

  • The mainstay of therapy in all seronegative spondyloarthropathies are anti-inflammatory drugs, which include NSAIDs such asibuprofenphenylbutazonediclofenacindomethacinnaproxen and COX-2 inhibitors, which reduce inflammation and pain. Indomethacin is a drug of choice. 2012 research showed that those with AS and elevated levels of acute phase reactants seem to benefit most from continuous treatment with NSAIDs.
  • Opioid painkillers

Medications used to treat the progression of the disease include the following:

  • Disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine can be used in people with peripheral arthritis. For axial involvement, evidence does not support sulfasalazine. Other DMARDS, such as methotrexate did not have enough evidence to prove their effect. Generally, systemic corticosteroids were not used due to lack of evidence. Local injection with corticosteroid can be used for certain people with peripheral arthritis.
  • Tumor necrosis factor-alpha (TNFα) blockers (antagonists), such as the biologics etanerceptinfliximabgolimumab and adalimumab, have shown good short-term effectiveness in the form of profound and sustained reduction in all clinical and laboratory measures of disease activity. Trials are ongoing to determine their long-term effectiveness and safety. The major drawback is the cost. An alternative is the new, orally-administered non-biologic apremilast, which inhibits TNF-α secretion.
  • Anti-interleukin-6 inhibitors such as tocilizumab, currently approved for the treatment of rheumatoid arthritis, and rituximab, a monoclonal antibody against CD20, are also undergoing trials.

Surgery

In severe cases of AS, surgery can be an option in the form of joint replacements, particularly in the knees and hips. Surgical correction is also possible for those with severe flexion deformities (severe downward curvature) of the spine, particularly in the neck, although this procedure is considered very risky.

In addition, AS can have some manifestations which make anesthesia more complex. Changes in the upper airway can lead to difficulties in intubating the airway, spinal and epidural anaesthesia may be difficult owing to calcification of ligaments, and a small number of people have aortic insufficiency. The stiffness of the thoracic ribs results in ventilation being mainly diaphragm-driven, so there may also be a decrease in pulmonary function.

Physical therapy

Though physical therapy remedies have been scarcely documented, some therapeutic exercises are used to help manage lower back, neck, knee, and shoulder pain. Some therapeutic exercises include:

  • Low intensity aerobic exercise
  • Transcutaneous electrical nerve stimulation (TENS)
  • Thermotherapy
  • Proprioceptive neuromuscular facilitation (PNF)
  • Exercise programs, either at home or supervised;
  • Group exercises;

Moderate-to-high impact exercises like jogging are generally not recommended or recommended with restrictions due to the jarring of affected vertebrae that can worsen pain and stiffness in some with AS.

Prognosis

Prognosis is related to disease severity. AS can range from mild to progressively debilitating and from medically controlled to refractory. Some cases may have times of active inflammation followed by times of remission resulting in minimal disability, while others never have times of remission and have acute inflammation and pain, leading to significant disability. As the disease progresses, it can cause the vertebrae and the lumbosacral joint to ossify, resulting in the fusion of the spine. This places the spine in a vulnerable state because it becomes one bone, which causes it to lose its range of motion as well as putting it at risk for spinal fractures. This not only limits mobility but reduces the affected person’s quality of life. Complete fusion of the spine can lead to a reduced range of motion and increased pain, as well as total joint destruction which could lead to a joint replacement.

Over a long-term period, osteopenia or osteoporosis of the AP spine may occur, causing eventual compression fractures and a back “hump”. Typical signs of progressed AS are the visible formation of syndesmophytes on X-rays and abnormal bone outgrowths similar to osteophytes affecting the spine. The fusion of the vertebrae paresthesia is a complication due to the inflammation of the tissue surrounding nerves.

Organs commonly affected by AS, other than the axial spine and other joints, are the heartlungseyescolon, and kidneys. Other complications are aortic regurgitationAchilles tendinitisAV node block and amyloidosis. Owing to lung fibrosis, chest X-rays may show apical fibrosis, while pulmonary function testing may reveal a restrictive lung defect. Very rare complications involve neurologic conditions such as the cauda equina syndrome.

Mortality

Mortality is increased in people with AS and circulatory disease is the most frequent cause of death. AS patients have an increased risk of 60% for cerebrovascular mortality, and an overall increased risk of 50% for vascular mortality.

As increased mortality in ankylosing spondylitis is related to disease severity, factors negatively affecting outcomes include:

  • Male sex
  • Plus 3 of the following in the first 2 years of disease:
    • Erythrocyte sedimentation rate (ESR) >30 mm/h
    • Unresponsive to NSAIDs
    • Limitation of lumbar spine range of motion
    • Sausage-like fingers or toes
    • Oligoarthritis
    • Onset <16 years old

Gait

The hunched position that often results from complete spinal fusion can have an effect on a person’s gait. Increased spinal kyphosis will lead to a forward and downward shift incenter of mass (COM). This shift in COM has been shown to be compensated by increased knee flexion and ankle plantarflexion. The gait of someone with ankylosing spondylitis often has a cautious pattern because they have decreased ability to absorb shock, and they cannot see the horizon.

Epidemiology

Ankylosing spondylitis prevalence is between 0.1 and 0.2% of the general population. The disease is most prevalent in Northern European countries, and seen least in people of Afro-Caribbean descent. The ratio of male to female disease is 3:1, however many rheumatologists believe the number of women with AS is underdiagnosed, as most women tend to experience milder cases of the disease. The majority of people with AS, including 95 percent of white people with the disease, express the HLA-B27 antigen and high levels of immunoglobulin A (IgA) in the blood.

Research

In 2007, a collaborative effort by an international team of researchers in the United Kingdom, Australia and the United States led to the discovery of two genes that also contribute to the cause of AS: ARTS-1 and IL23R. The findings were published in the November 2007 edition of Nature Genetics, a journal that emphasizes research on the genetic basis for common and complex diseases. Together with HLA-B27, these two genes account for roughly 70 percent of the overall incidence of the disease.

See also Acutreatment.

Treatedwith needles placed at SP6, ST36, TF4 and GB2.




2 responses to “Ankylosing spondylitis”

  1. Christin Cockrell says:

    Once once more, manyy organisations say their plan is examined howsever
    what ccurs is thyat they show that the foremost IT programs can be seen to be engaged on gear
    at a disaster recovery web site.

Leave a Reply

Your email address will not be published. Required fields are marked *